Literature DB >> 24336348

Comparison of hepatic transcription profiles of locked ribonucleic acid antisense oligonucleotides: evidence of distinct pathways contributing to non-target mediated toxicity in mice.

Satoko Kakiuchi-Kiyota1, Petra H Koza-Taylor, Srinivasa R Mantena, Linda F Nelms, Ahmed E Enayetallah, Brett D Hollingshead, Andrew D Burdick, Lori A Reed, James A Warneke, Lawrence O Whiteley, Anne M Ryan, Nagappan Mathialagan.   

Abstract

Development of LNA gapmers, antisense oligonucleotides used for efficient inhibition of target RNA expression, is limited by non-target mediated hepatotoxicity issues. In the present study, we investigated hepatic transcription profiles of mice administered non-toxic and toxic LNA gapmers. After repeated administration, a toxic LNA gapmer (TS-2), but not a non-toxic LNA gapmer (NTS-1), caused hepatocyte necrosis and increased serum alanine aminotransferase levels. Microarray data revealed that, in addition to gene expression patterns consistent with hepatotoxicity, 17 genes in the clathrin-mediated endocytosis (CME) pathway were altered in the TS-2 group. TS-2 significantly down-regulated myosin 1E (Myo1E), which is involved in release of clathrin-coated pits from plasma membranes. To map the earliest transcription changes associated with LNA gapmer-induced hepatotoxicity, a second microarray analysis was performed using NTS-1, TS-2, and a severely toxic LNA gapmer (HTS-3) at 8, 16, and 72 h following a single administration in mice. The only histopathological change observed was minor hepatic hypertrophy in all LNA groups across time points. NTS-1, but not 2 toxic LNA gapmers, increased immune response genes at 8 and 16 h but not at 72 h. TS-2 significantly perturbed the CME pathway only at 72 h, while Myo1E levels were decreased at all time points. In contrast, HTS-3 modulated DNA damage pathway genes at 8 and 16 h and also modulated the CME pathway genes (but not Myo1E) at 16 h. Our results may suggest that different LNAs modulate distinct transcriptional genes and pathways contributing to non-target mediated hepatotoxicity in mice.

Entities:  

Keywords:  LNA gapmers; antisense oligonucleotide; clathrin-mediated endocytosis; hepatotoxicity; microarray analysis

Mesh:

Substances:

Year:  2013        PMID: 24336348     DOI: 10.1093/toxsci/kft278

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  23 in total

Review 1.  Managing the sequence-specificity of antisense oligonucleotides in drug discovery.

Authors:  Peter H Hagedorn; Bo R Hansen; Troels Koch; Morten Lindow
Journal:  Nucleic Acids Res       Date:  2017-03-17       Impact factor: 16.971

Review 2.  Therapeutic targeting of microRNAs: current status and future challenges.

Authors:  Zhonghan Li; Tariq M Rana
Journal:  Nat Rev Drug Discov       Date:  2014-07-11       Impact factor: 84.694

Review 3.  HDL and microRNA therapeutics in cardiovascular disease.

Authors:  Danielle L Michell; Kasey C Vickers
Journal:  Pharmacol Ther       Date:  2016-09-03       Impact factor: 12.310

4.  BNANC Gapmers Revert Splicing and Reduce RNA Foci with Low Toxicity in Myotonic Dystrophy Cells.

Authors:  Kassie S Manning; Ashish N Rao; Miguel Castro; Thomas A Cooper
Journal:  ACS Chem Biol       Date:  2017-09-05       Impact factor: 5.100

5.  Nephrotoxic antisense oligonucleotide SPC5001 induces kidney injury biomarkers in a proximal tubule-on-a-chip.

Authors:  Tom T G Nieskens; Otto Magnusson; Patrik Andersson; Magnus Söderberg; Mikael Persson; Anna-Karin Sjögren
Journal:  Arch Toxicol       Date:  2021-05-07       Impact factor: 6.168

6.  Mesyl phosphoramidate backbone modified antisense oligonucleotides targeting miR-21 with enhanced in vivo therapeutic potency.

Authors:  Olga A Patutina; Svetlana K Gaponova Miroshnichenko; Aleksandra V Sen'kova; Innokenty A Savin; Daniil V Gladkikh; Ekaterine A Burakova; Alesya A Fokina; Mikhail A Maslov; Elena V Shmendel'; Mattew J A Wood; Valentin V Vlassov; Sidney Altman; Dmitry A Stetsenko; Marina A Zenkova
Journal:  Proc Natl Acad Sci U S A       Date:  2020-12-07       Impact factor: 12.779

Review 7.  Epigenome-modifying tools in asthma.

Authors:  Peter O Brook; Mark M Perry; Ian M Adcock; Andrew L Durham
Journal:  Epigenomics       Date:  2015-10-07       Impact factor: 4.778

8.  Deletion of murine Arv1 results in a lean phenotype with increased energy expenditure.

Authors:  W R Lagor; F Tong; K E Jarrett; W Lin; D M Conlon; M Smith; M Y Wang; B O Yenilmez; M G McCoy; D W Fields; S M O'Neill; R Gupta; A Kumaravel; V Redon; R S Ahima; S L Sturley; J T Billheimer; D J Rader
Journal:  Nutr Diabetes       Date:  2015-10-19       Impact factor: 5.097

Review 9.  Advanced In vivo Use of CRISPR/Cas9 and Anti-sense DNA Inhibition for Gene Manipulation in the Brain.

Authors:  Brandon J Walters; Amber B Azam; Colleen J Gillon; Sheena A Josselyn; Iva B Zovkic
Journal:  Front Genet       Date:  2016-01-12       Impact factor: 4.599

10.  DNA/RNA heteroduplex oligonucleotide for highly efficient gene silencing.

Authors:  Kazutaka Nishina; Wenying Piao; Kie Yoshida-Tanaka; Yumiko Sujino; Tomoko Nishina; Tsuyoshi Yamamoto; Keiko Nitta; Kotaro Yoshioka; Hiroya Kuwahara; Hidenori Yasuhara; Takeshi Baba; Fumiko Ono; Kanjiro Miyata; Koichi Miyake; Punit P Seth; Audrey Low; Masayuki Yoshida; C Frank Bennett; Kazunori Kataoka; Hidehiro Mizusawa; Satoshi Obika; Takanori Yokota
Journal:  Nat Commun       Date:  2015-08-10       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.